Naltrexone and buprenorphine combination in the treatment of opioid dependence
The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Naltrexone treatment has demonstrated some advantages for special populations of heroin addicted individuals, but patients' compliance seems to be very poor, with a low adherence and low retention rate. Kappa-opioid system overdrive seems to contribute to opioid protracted abstinence syndrome, with dysphoria and psychosomatic symptoms during naltrexone treatment. The objective of this observational study was to determine the effectiveness of a functional k antagonist in improving naltrexone treatment outcome. A partial mu agonist/kappa antagonist (buprenorphine) and a mu antagonist (naltrexone) were combined during a 12 weeks protocol, theoretically leaving k antagonism as the major medication effect. Sixty patients were submitted to outpatient rapid detoxification utilizing buprenorphine and opioid antagonists. Starting on the fifth day, 30 patients (group A) received naltrexone alone. Alternatively, 30 patients (group B) received naltrexone (50mg oral dose) plus buprenorphine (4 mg sublingual) for the 12 weeks of the observational study. The endpoints of the study were: retention in treatment, negative urinalyses, changes in psychological symptoms (Symptom Checklist-90 Revised: SCL-90) and craving scores (visual analysis scale (VAS)). Thirty-four subjects (56.67%) completed the 12 weeks study. Twenty-one patients (35.0%) had all urine samples negative for opiates and cocaine. nine subjects (15.0%) had urine samples negative for cocaine and opiates for the last 4 weeks of the study. five subjects (8.3%) continued to use cocaine during the 12 weeks of the study. No significant change in pupillary diameter after buprenorphine administration was evidenced during clinical observations from baseline across the weekly measurements. Retention rates in group A (naltrexone) and group B (naltrexone + buprenorphine) at week 12 were respectively 40% (12 patients) and 73.33% (22 patients), with a significant difference in favour of group B (p= 0.018). Patients treated with naltrexone in combination with buprenorphine (B patients) showed a significantly lower rate of positive urines for morphine (4.45%) and cocaine metabolites (9.09%) than those treated with naltrexone alone (A) (25%, morphine; 33.33% cocaine) (p< 0.05; p< 0.05). Irritability, depression, tiredness, psychosomatic symptoms and craving scores decreased significantly less in Group A patients than in group B patients. The dysfunction of opioid system with kappa receptors hyper-activation provoked by heroin exposure, probably underlying dysphoric and psychosomatic symptoms during naltrexone treatment, seems to be counteracted, at least in part, by buprenorphine. The combination of buprenorphine and naltrexone may significantly improve the outcome of opioid antagonists treatment in terms of retention, negative urinalyses, and reduced dysphoria, mood symptoms and craving.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition to its ability to reduce symptoms of withdrawal and craving in OUD, buprenorphine may also have a therapeutic impact on dysphoria (119), potentially leading to improvements in treatment retention and quality of life.”
From Craving in Opioid Use Disorder: From Neurobiology to Clinical Practice (2019) · cites this paper as [119]
In the citing paper
“Gerra and colleagues [50] observed a greater reduction of irritability, depression, tiredness, and psychosomatic symptoms in the BUP + naltrexone group vs. naltrexone alone group after 12 weeks of treatment.”
From The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review (2018) · cites this paper as [50]
In the citing paper
“Three additional studies investigating the course of depressive symptoms in opiate dependence patients treated with BUP were also considered in addition to the Striebel case (a total of 248 patients) [48,49,50].”
From The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review (2018) · cites this paper as [50]
In the citing paper
“Bodkin and colleagues [42] and Gerra et al. [50] even reported some cases of irritability, anxiety, and dysphoria, which led to drop-out from the study of implicated patients.”
From The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review (2018) · cites this paper as [50]
In the citing paper
“Another important shortcoming is represented by the modest sample size of almost all the samples (with the exclusion of some studies [45,50,51]) which does not allow to obtain a good statistical significance and, hence, does not allow the generalization of the main findings.”
From The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review (2018) · cites this paper as [50]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Diagnostic and Statistical Manual of Mental Disorders
(2012) · SpringerReference · doi:10.1007/springerreference_121117 · Cited by 20,570
A JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
(1909) · Journal of the American Medical Association · doi:10.1001/jama.1909.02550020033007 · Cited by 7,866
Dynorphin Is a Specific Endogenous Ligand of the κ Opioid Receptor
Chavkin, C., James, I. F., & Goldstein, A. (1982) · Science · doi:10.1126/science.6120570 · Cited by 1,168 · cited 1×
“…Trujillo and Akil, 1989; Smiley et al., 1990; Trujillo et al., 1990), suggesting that dynorphin, an endogenous k agonist (Chavkin et al., 1982; Corbett et al., 1982), might function as part of a homeostatic system to oppose the mood-enhancing and reinforcing effects of morphine (Spanagel et…”
BackgroundOpposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway.
Spanagel, R., Herz, A., & Shippenberg, T. S. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.6.2046 · Cited by 1,014
Neural Mechanisms of Drug Reinforcementa
KOOB, G. F. (1992) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1992.tb25966.x · Cited by 610
(1962) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1962.tb27008.x · Cited by 586
Dynorphin1–8 and dynorphin1–9 are ligands for the κ-subtype of opiate receptor
Corbett, A. D., Paterson, S. J., McKnight, A. T., Magnan, J., & Kosterlitz, H. W. (1982) · Nature · doi:10.1038/299079a0 · Cited by 447 · cited 1×
“…Trujillo and Akil, 1989; Smiley et al., 1990; Trujillo et al., 1990), suggesting that dynorphin, an endogenous k agonist (Chavkin et al., 1982; Corbett et al., 1982), might function as part of a homeostatic system to oppose the mood-enhancing and reinforcing effects of morphine (Spanagel et…”
BackgroundBuprenorphine Treatment of Refractory Depression
Bodkin, J. A., Zornberg, G. L., Lukas, S. E., & Cole, J. O. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199502000-00008 · Cited by 346
Gonzalez, J. P., & Brogden, R. N. (1988) · Drugs · doi:10.2165/00003495-198835030-00002 · Cited by 314
Research works printed but not linked: 14
- Bachs L, 2003, Tidsskr Nor Laegeforen, 123, 1665
- Corbett A D, 1982, Nature, 291, 591
- Derogatatis L R, 1977, Administration, Scoring, and Procedure Manual – 1
- Giordano A L, 1990, J Pharmacol Exp Ther, 255, 536
- Grinenko A, 2003, Vestn Ross Akad Med Nauk, 10, 54
- 10.1111/j.1521-0391.2003.tb00552.x · doi:10.1111/j.1521-0391.2003.tb00552.x · Paper page
- Madoz-Gurpide A, 2004, Actas Esp Psiquiatr, 32, 199
- Mendelson J H, 1992, Neuropsychopharmacology, 7, 157
- O'Brien C P, 1986, NIDA Res Monogr, 67, 373
- Renault P F, 1981, NIDA Res Monogr, 28, 11
- Smiley P L, 1990, Journal of Pharmacology and Experimental Therapeutics, 253, 938
- Trujillo K A, 1989, National Institute on Drug Abuse Research Monograph, 95, 550
- van Brussel G H, 2001, Ned Tijdschr Geneeskd, 145, 1452
- Walsh S L, 1995, Journal of Pharmacology and Experimental Therapeutics, 274, 361
Cited by
The role of the dynorphin–κ opioid system in the reinforcing effects of drugs of abuse
Wee, S., & Koob, G. F. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1825-8 · Cited by 398
“alone in heroin-dependent humans (Gerra et al. 2006).”
InfluentialNeuroscience of Addiction: Relevance to Prevention and Treatment
Volkow, N. D., & Boyle, M. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17101174 · Cited by 322
Veilleux, J. C., Colvin, P. J., Anderson, J., York, C., & Heinz, A. J. (2010) · Clinical Psychology Review · doi:10.1016/j.cpr.2009.10.006 · Cited by 336
The Kappa Opioid Receptor: From Addiction to Depression, and Back
Lalanne, L., Ayranci, G., Kieffer, B. L., & Lutz, P.-E. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00170 · Cited by 225
“Clinical trials are currently on-going to assess KOR antagonists as a treatment for depression (22), in particular in the context of addicted patients suffering from comorbid depressive conditions (23, 24).”
BackgroundOpioid dependence treatment: options in pharmacotherapy
Stotts, A. L., Dodrill, C. L., & Kosten, T. R. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903037168 · Cited by 222
“Gerra and co-workers [134] conducted an observational study suggesting potential benefit from the combination of lower doses of buprenorphine (4 mg) and naltrexone as a detoxification and subsequent maintenance strategy to counteract the protracted opioid abstinence syndrome common after detoxification (dysphoria and…”
Metadata
- Authors
- Gerra, G., Fantoma, A., & Zaimovic, A.
- Affiliations
- National Department on Drug Policy, Rome, Italy
- Addiction Research Centre, Ser.T., AUSL, Parma, Italy
- ORCID
- Gerra, G.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2006-11
- Volume
- 20
- Issue
- 6
- Pages
- 806-814
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2039166465
- Cited by
- 106
- References
- 53
- Citations by year
- 2026: 6 · 2025: 2 · 2024: 1 · 2023: 3 · 2022: 4 · 2021: 5 · 2020: 4 · 2019: 6 · 2018: 8 · 2017: 6 · 2016: 2 · 2015: 7 · 2014: 8 · 2013: 7 · 2012: 12
- FWCI
- 4.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- opioid use disorder, heroin addiction, naltrexone, buprenorphine, combination pharmacotherapy, rapid detoxification, treatment retention, relapse, cocaine use, craving, pupil size, opioid antagonists, medication adherence, withdrawal syndrome, dysphoria, psychosomatic symptoms, urine drug testing, outpatient care
- MeSH terms
- Adult, Affect, Buprenorphine, Cocaine, Female, Heroin Dependence, Humans, Liver, Male, Naltrexone, Narcotic Antagonists, Opioid-Related Disorders, Psychiatric Status Rating Scales, Substance Abuse Detection, Survival Analysis, Cocaine-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Naltrexone and buprenorphine combination in the treatment of opioid dependence. https://app.cochat.ai/papers/10.1177/0269881106060835
- The paper
- Gerra, G., Fantoma, A., & Zaimovic, A. (2006). Naltrexone and buprenorphine combination in the treatment of opioid dependence. Journal of Psychopharmacology. https://doi.org/10.1177/0269881106060835
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.